Tricosanamide | 74172-30-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Tricosanamide
• CAS: 74172-30-8
• 化学式: C₂₃H₄₇NO
• 分子量: 353.6
• InChiKey: HLYCHHRAFCZZDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.5
• 重原子数：
  25
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Thermochromic microencapsulated pigments
  申请人：THE PILOT INK CO., LTD.

  公开号：EP1084860A2

  公开（公告）日：2001-03-21

  Disclosed is a thermochromic microencapsulated pigment which comprises as four essential components (a) an electron-donating chromatic organic compound, (b) an electron-accepting compound, (c) a reaction medium determining the temperatures at which the color reactions of component (a) with component (b) take place, and (d) a color change temperature regulator, the color change temperature regulator (d) comprising one or more compounds selected from the group consisting of esters, alcohols, ketones, acid amides, hydrocarbons, and fatty acids and having a melting point Y (°C) satisfying the relationship (X+30)°C≤Y≤200°C, wherein X (°C) is the melting point of component (c), and the four essential components being microencapsulated.

  本发明公开了一种热致变色微胶囊颜料，它由四种基本成分组成：(a) 一种电子供色有机化合物；(b) 一种电子受色化合物；(c) 一种决定成分(a)与成分(b)发生颜色反应的温度的反应介质；(d) 一种变色温度调节剂、变色温度调节剂(d)包括一种或多种从酯、醇、酮、酸酰胺、烃和脂肪酸组成的组中选出的化合物，其熔点 Y(℃)满足(X+30)℃≤Y≤200℃的关系，其中 X(℃)是组分(c)的熔点，四种基本组分被微胶囊化。
• DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：EP3456317A1

  公开（公告）日：2019-03-20

  The disclosure relates to di-aliphatic substituted PEGylated lipids and to methods of their preparation. The disclosure also relates to lipid conjugates containing di-aliphatic substituted PEGylated lipids, and to the use of di-aliphatic substituted PEGylated-lipid conjugates in drug delivery.

  本公开涉及二脂肪族取代的 PEG 化脂类及其制备方法。本发明还涉及含有二脂肪族取代的 PEG 化脂质的脂质共轭物，以及二脂肪族取代的 PEG 化脂质共轭物在给药中的应用。
• THIAMINE COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：Shanghai Raising Pharmaceutical Co., Ltd.

  公开号：EP3889160A1

  公开（公告）日：2021-10-06

  The embodiments of the present invention provide a series of thiamine compounds having a hydrocarbon group or a substituted hydrocarbon group attached at (I), wherein the compounds have an inhibitory effect on Aβ40 and/or Aβ42.

  本发明的实施例提供了一系列具有烃基的硫胺化合物 或取代的烃基连接在(I)处，其中化合物对 Aβ40 和/或 Aβ42 具有抑制作用。
• Use of ceramides and LPLs in diagnosing CVD
  申请人：ZORA BIOSCIENCES, OY

  公开号：US10184932B2

  公开（公告）日：2019-01-22

  The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

  本发明特别提供了一种方法及其用途，通过测定生物样本中至少一种式I神经酰胺或一种式II和/或III溶血磷脂以及至少一种式IV、V、VI、VII和/或VIII溶血磷脂的浓度，并将这些浓度与对照组进行比较，从而预测冠心病事件，如AMI、ACS、中风和冠心病死亡。如果发现至少一种式 I 神经酰胺或式 II 和/或式 III 溶血磷脂的浓度升高，而至少一种式 IV、V、VI、VII 和/或 VIII 溶血磷脂的浓度降低，则表明受试者发生一种或多种心血管事件的风险升高。本公开还提供了一种诊断急性缺血患者的方法及其用途。还提供了包含相同成分的试剂盒和组合物，用于预测和/或诊断 CV 事件。
• Ceramides and their use in diagnosing CVD
  申请人：ZORA BIOSCIENCES, OY

  公开号：US10197582B2

  公开（公告）日：2019-02-05

  The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

  本发明特别提供了一种方法及其用途，通过测定生物样本中至少一种 A 组神经酰胺和至少一种 B 组神经酰胺的浓度，并将这些浓度与对照组进行比较，从而预测冠心病并发症，如急性心肌梗死、冠状动脉综合征、中风和冠心病死亡。如果发现至少一种 A 组神经酰胺的浓度降低，至少一种 B 组神经酰胺的浓度升高，则表明受试者患一种或多种心血管并发症的风险增加。此外，还提供了新鉴定的神经酰胺分子子集、其标记版本以及包含这些分子的试剂盒和组合物，用于预测和/或诊断冠心病并发症。